MINNEAPOLIS--(BUSINESS WIRE)--Pelvital, a privately held medical device company that has developed Flyte™, a clinically proven, FDA-cleared, non-surgical treatment for female stress urinary ...

The new Flyte App and Provider Portal offer enhanced tracking and personalization for women suffering from mild to severe SUI, improving care outcomes and provider-patient collaboration Flyte, an ...

• The Flyte® device resulted in continence or clinically significant improvement in 2-12 weeks, as evidenced by reduction in 24-hour pad weight. • Transvaginal mechanotherapy presents a new and ...

The majority of adult women in the US suffer urinary incontinence (UI), with the most common form of UI being Stress Urinary Incontinence (SUI), which is often caused by weak pelvic floor muscles. SUI ...

Eagan-based medical device startup Pelvital this week said it has raised an additional $2.32 million in seed funding to help treat stress urinary incontinence (SUI) in women. Pelvital raised its first ...

Eagan-based medical device startup Pelvital has raised $2.68 million in its first round of venture capital funding, the company announced Tuesday. Indianapolis-based Boomerang Ventures led the round, ...

Pelvital’s first product, Flyte, is a clinically proven, in-home treatment for stress urinary incontinence, designed to treat weakened pelvic floor muscles to reduce bladder leaks, restore continence ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eagan-based Pelvital raised an ...

The MarketWatch News Department was not involved in the creation of this content. The new Flyte App and Provider Portal offer enhanced tracking and personalization for women suffering from mild to ...

MINNEAPOLIS--(BUSINESS WIRE)--Pelvital, a privately held medical device company that has developed Flyte™, a clinically proven, FDA-cleared, non-surgical treatment for female stress urinary ...